Antares Pharma, Inc. (ATRS)
Stock Price:
$2.61 USD
-0.07 (-2.61%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
Pre-market: $2.70 +0.09 (3.45%) Aug 3, 7:00 AM
Key Info
| Market Cap |
432.11M |
| Revenue (ttm) |
133.66M |
| Net Income (ttm) |
1.16M |
| Shares Out |
165.56M |
| EPS (ttm) |
0.01 |
| PE Ratio |
261.00 |
| Forward PE |
34.72 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 31, 2020 |
| Last Price |
$2.61 |
| Previous Close |
$2.68 |
| Change ($) |
-0.07 |
| Change (%) |
-2.61% |
| Day's Open |
2.66 |
| Day's Range |
2.56 - 2.68 |
| Day's Volume |
1,204,927 |
| 52-Week Range |
1.60 - 5.13 |
More Stats
| Market Cap |
432.11M |
| Enterprise Value |
428.83M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
165.56M |
| Float |
152.86M |
| EPS (basic) |
0.02 |
| EPS (diluted) |
0.01 |
| FCF / Share |
0.06 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.38% |
| FCF Yield |
2.16% |
| Payout Ratio |
n/a |
| Shares Short |
5.34M |
| Short Ratio |
5.57 |
| Short % of Float |
3.38% |
| Beta |
1.35 |
| PE Ratio |
261.00 |
| Forward PE |
34.72 |
| P/FCF Ratio |
46.19 |
| PS Ratio |
3.23 |
| PB Ratio |
8.25 |
| Revenue |
133.66M |
| Operating Income |
4.60M |
| Net Income |
1.16M |
| Free Cash Flow |
9.36M |
| Net Cash |
3.29M |
| Net Cash / Share |
0.02 |
| Gross Margin |
54.91% |
| Operating Margin |
3.44% |
| Profit Margin |
0.90% |
| FCF Margin |
7.00% |
| ROA |
2.44% |
| ROE |
2.40% |
| ROIC |
5.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.25*
(139.46% upside)
Low
4.50
Current: $2.61
High
8.00
Target: 6.25
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 124 | 63.55 | 54.52 | 52.22 | 45.66 | 26.50 | 20.62 | 22.58 | 16.46 | 12.82 |
| Revenue Growth | 94.9% | 16.58% | 4.39% | 14.38% | 72.28% | 28.53% | -8.67% | 37.17% | 28.39% | - |
| Gross Profit | 73.39 | 32.49 | 27.05 | 23.41 | 26.20 | 15.26 | 11.42 | 13.06 | 9.66 | 8.55 |
| Operating Income | 0.99 | -4.10 | -15.59 | -24.12 | -20.46 | -35.11 | -20.85 | -11.45 | -4.44 | -6.03 |
| Net Income | -2.03 | -6.52 | -16.74 | -24.34 | -20.66 | -35.15 | -20.51 | -11.43 | -4.39 | -6.09 |
| Shares Outstanding | 163 | 157 | 156 | 155 | 147 | 131 | 127 | 110 | 96.99 | 83.17 |
| Earnings Per Share | -0.01 | -0.04 | -0.11 | -0.16 | -0.14 | -0.27 | -0.16 | -0.10 | -0.05 | -0.07 |
| Operating Cash Flow | -10.62 | -17.32 | -23.09 | -15.20 | -28.20 | -26.33 | -14.97 | -10.47 | -1.93 | -6.08 |
| Capital Expenditures | 2.65 | 6.65 | 0.73 | -4.88 | -5.64 | -4.66 | -2.74 | -3.26 | -0.32 | -0.06 |
| Free Cash Flow | -7.97 | -10.68 | -22.36 | -20.08 | -33.84 | -31.00 | -17.71 | -13.73 | -2.25 | -6.14 |
| Cash & Equivalents | 45.72 | 27.89 | 31.56 | 27.72 | 47.91 | 40.03 | 63.08 | 73.21 | 31.37 | 9.85 |
| Total Debt | 47.09 | 25.13 | 24.86 | - | - | - | - | - | - | - |
| Net Cash / Debt | -1.36 | 2.77 | 6.70 | 27.72 | 47.91 | 40.03 | 63.08 | 73.21 | 31.37 | 9.85 |
| Assets | 133 | 88.28 | 74.34 | 66.33 | 84.56 | 68.77 | 88.93 | 95.53 | 41.96 | 15.14 |
| Liabilities | 78.25 | 49.28 | 40.79 | 21.11 | 17.52 | 27.58 | 18.22 | 8.98 | 10.82 | 8.51 |
| Book Value | 54.50 | 39.00 | 33.55 | 45.22 | 67.04 | 41.20 | 70.71 | 86.55 | 31.14 | 6.63 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Antares Pharma, Inc. |
| Country |
United States |
| Employees |
178 |
| CEO |
Robert F. Apple |
Stock Information
| Ticker Symbol |
ATRS |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Instruments & Supplies |
| Unique Identifier |
NASDAQ: ATRS |
| IPO Date |
October 2, 1996 |
Description
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.